Company Performance Metrics
- Christopher Slapak: Chief Medical Officer
- Robert Ang: President and CEOPast Role: Bavarian Nordic, Senior Vice President of Business Development
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T
cells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential.
The company is taking a fundamentally novel approach to targeting cancer selectively by developing hematopoietic stem cells (HSCs) that have been engineered to be protected from specifically targeted immunotherapies. These HSCs are designed to generate healthy, functional cells that are also protected from depletion by cancer-targeted therapies.
